7. Conclusions
cardiovascular disease, dyslipidemia
PAD, CARDIOVASCULAR DISEASE, DYSLIPIDEMIA
In hemodialysis patients with dyslipidemia receiving conventional statin-based therapy, the add-on high-dose EPA/DHA treatment improved their ABI. Therefore, the dose-dependent effects of EPA/DHA on RLP-C levels may be an important factor in PAD improvement. Clinicians involved in dialysis care might focus on RLP-C, an atherogenic lipid, when considering residual cardiovascular disease risk in hemodialysis patients, and it may also be worthwhile to consider specifically screening patients with elevated RLP-C levels. Moreover, EPA/DHA may be a good indication for improving the ABI in hemodialysis patients with elevated RLP-C. The reduction in RLP-C levels by EPA/DHA has the potential to improve patients’ quality of life and contribute to a reduction in medical costs, providing a multitude of benefits.